The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2010MicroRNAs as Biomarkers for Parkinson's Disease; A Comparison of CSF and Blood
Objective/Rationale:
We, and many other groups, hypothesize that miRNAs have the potential to be selective and sensitive diagnostic indicators for Parkinson’s disease. The focus of this project is to... -
Target Validation, 2010Validation of FKBP Inhibitors to Target Alpha-synuclein Pathology in Pre-clinical Model Brain
Objective/Rationale:
FK506 Binding Proteins (FKBPs) are enzymes that play a role in protein folding. FKBPs are highly expressed in human brain and are thought to be involved in neurodegenerative... -
Target Validation, 2010Does the Ubiquitin Ligase, Nedd4, Protect Against Alpha-Synucleinopathy?
Objective/Rationale:
The cellular mechanisms that normally limit accumulation of alpha-synuclein are unclear. We have found that the enzyme, Nedd4, tags alpha-synuclein for destruction in lysosomes... -
Rapid Response Innovation Awards, 2010Genetic Dissection of Parkinson's Disease Vulnerable Dopaminergic Neurons Population
Objective/Rationale:
There is a clear heterogeneity in the susceptibility of dopamine neurons to Parkinson’s disease. Indeed, neurons of the substancia nigra ventral tier are specifically lost in... -
Rapid Response Innovation Awards, 2010The Role of Alpha-synuclein in the Pathogenesis of Parkinson's Disease in a Pre-clinical Model
Objective/Rationale:
We hypothesized that alpha-synuclein increased level and accumulation within the target neurons in the affected model acts as a trigger mechanism for activation of additional... -
MJFF Research Grant, 2010Clinical Assessment of Patients with PD Who Underwent DAT Scan and FDG PET at the Early Stages of Their Extra-Pyramidal Disorder as Part of Their Initial Workup
Objective/Rationale:
Ashkenazi Jewish PD patients in Israel have a 14% chance of carrying the G2019S LRRK2 mutation and 18% of carrying mutations in the GBA gene. Little is known on the association...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.